The unbound CXCL12 in the TME of PDA tumors lacking the CXCL12–KRT19 coating will elicit the other immune-suppressive effect of CXCR4, which is inhibition of other chemokine receptors to mediate directed migration (8). The gene discussed is CXCL12; the disease is Patent ductus arteriosus.